Santa Clara, CA, United States of America

Roland Joseph Billedeau

USPTO Granted Patents = 23 (Patent Applications = 6)

EPO Patents = 6 (Patent Applications = 10)

Average Co-Inventor Count = 4.2

ph-index = 5

Forward Citations = 104(Granted Patents)

Location History:

Clifton, NJ (US) (2013)
Santa Clara, CA (US) (2001 - 2024)

Company Filing History:

8 out of 30

Calithera Biosciences, Inc.

Hoffmann-la Roche Inc.

patents

4. 1 out of 174

Agouron Pharmaceuticals, Inc.

patents

5. 1 out of 1

Antengent Therapeutics Limited

patent

6. 1 out of 1

Precision Pharmaceuticals, Inc.

patent

7. 1 out of 1

Antengene Therapeutics Limited

patent

8. 3 out of 832,680

Other

patents

Years Active: 2001-2025

Loading Chart...

23 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12421273 - Ectonucleotidase inhibitors and methods of use thereof (2025-09-23),

2. 12054501 - Compositions and methods for inhibiting arginase activity (2024-08-06),

3. 11858957 - Ectonucleotidase inhibitors and methods of use thereof (2024-01-02),

4. 11208414 - Ectonucleotidase inhibitors and methods of use thereof (2021-12-28),

5. 11078228 - Ectonucleotidase inhibitors and methods of use thereof (2021-08-03),

6. 11034715 - Ectonucleotidase inhibitors and methods of use thereof (2021-06-15),

7. 11021495 - Compositions and methods for inhibiting arginase activity (2021-06-01),

8. 10597411 - Compositions and methods for inhibiting arginase activity (2020-03-24),

9. 10570167 - Ectonucleotidase inhibitors and methods of use thereof (2020-02-25),

10. 10472364 - Ectonucleotidase inhibitors and methods of use thereof (2019-11-12),

11. 10287303 - Compositions and methods for inhibiting arginase activity (2019-05-14),

12. 8940741 - Inhibitors of bruton's tyrosine kinase (2015-01-27),

13. 8729078 - Inhibitors of bruton's tyrosine kinase (2014-05-20),

14. 8481540 - Inhibitors of bruton's tyrosine kinase (2013-07-09),

15. 8361962 - Tricyclic inhibitors of JAK (2013-01-29),

Title: The Innovator: Roland Joseph Billedeau

Introduction: Roland Joseph Billedeau, based in Santa Clara, California, is a prominent inventor with a remarkable portfolio of 21 patents. His innovative contributions primarily focus on the field of pharmaceuticals, particularly in cancer treatment.

Latest Patents: Billedeau's latest patents include groundbreaking developments in ectonucleotidase inhibitors. These inventions encompass novel heterocyclic compounds and their pharmaceutical preparations that show promise in treating or preventing cancer. Specifically, his patents detail compounds with CD73 inhibitory activity, further advancing therapeutic strategies against various forms of this devastating disease.

Career Highlights: Throughout his career, Billedeau has made significant strides in biomedicine, working with well-respected institutions such as Calithera Biosciences, Inc. and Roche Palo Alto LLC. His expertise and innovative mindset have positioned him as a key player in the biotechnology sector, where he has consistently contributed to advancements in cancer therapeutics.

Collaborations: In his journey, Billedeau has collaborated with notable colleagues, including Lijing Chen and Jim W Li. These partnerships have fostered an environment of creativity and innovation, driving forward the development of new methods and compounds in the medical field.

Conclusion: Roland Joseph Billedeau stands out as an influential inventor whose work has the potential to change the landscape of cancer treatment. With a strong foundation of patented innovations and collaborative efforts, he continues to advance the science of therapeutics, showcasing the vital role of inventors in overcoming health challenges.

This text is generated by artificial intelligence and may not be accurate.